Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in a phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), a phase II study in adults with certain genetically defined solid tumor (INI1-negative tumors, SMARCA4-negative tumors or synovial sarcomas) and a phase I study in children with certain INI1-negative tumors or synovial sarcoma.
The company’s track record has been strong, with the company beating estimates in three of the last four quarters and missing on one occasion, with an average positive earnings surprise of 7.59%.
Currently, Epizyme has a Zacks Rank # (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Epizyme posted narrower-than-expected loss in the second quarter of 2016. While our consensus called for a loss of 50 cents per share, the company reported a loss of 49 cents.
Revenues: The company reported collaboration revenues of $0.5 million.
Key Stats: Epizyme continues to progress with candidates on its pipeline. The company Epizyme entered into a collaboration agreement with Roche’s Genentech to evaluate tazemetostat, in combination Tecentriq (atezolizumab). The combination will be evaluated in a phase Ib study for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Check back later for our full write up on earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Image: Bigstock
Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q2
Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in a phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), a phase II study in adults with certain genetically defined solid tumor (INI1-negative tumors, SMARCA4-negative tumors or synovial sarcomas) and a phase I study in children with certain INI1-negative tumors or synovial sarcoma.
The company’s track record has been strong, with the company beating estimates in three of the last four quarters and missing on one occasion, with an average positive earnings surprise of 7.59%.
Currently, Epizyme has a Zacks Rank # (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Epizyme posted narrower-than-expected loss in the second quarter of 2016. While our consensus called for a loss of 50 cents per share, the company reported a loss of 49 cents.
Revenues: The company reported collaboration revenues of $0.5 million.
Key Stats: Epizyme continues to progress with candidates on its pipeline. The company Epizyme entered into a collaboration agreement with Roche’s Genentech to evaluate tazemetostat, in combination Tecentriq (atezolizumab). The combination will be evaluated in a phase Ib study for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
EPIZYME INC Price
EPIZYME INC Price | EPIZYME INC Quote
Check back later for our full write up on earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>